| Masihuddin Ahmed, | |
|
29 E 29th St, Bayonne, NJ 07002-4695 | |
| (201) 858-5000 | |
| Not Available |
| Full Name | Masihuddin Ahmed |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 29 E 29th St, Bayonne, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417526997 | NPI | - | NPPES |
| Entity Name | Brookview Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871965855 PECOS PAC ID: 9537420450 Enrollment ID: O20180309000532 |
News Archive
Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.
Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.
Scientists have long been worried about the possible harmful effects of regular cellular phone use, but so far no study has managed to produce clear results. Currently, cell phones are classified as carcinogenic category 2b - potentially carcinogenic to humans - by the International Agency for Research on Cancer (IARC).
A new study has shown aspirin cuts down the death rates from a range of cancers. The study reviewed data from eight previous trials involving more than 25,000 patients found that those who took just 75mg of aspirin a day (one-eighth of a normal dose) could reduce their death rates from cancer by 21% with benefits continuing long after patients stopped taking the pill.
Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Masihuddin Ahmed, 29 E 29th St, Bayonne, NJ 07002-4695 Ph: (774) 210-2167 | Masihuddin Ahmed, 29 E 29th St, Bayonne, NJ 07002-4695 Ph: (201) 858-5000 |
News Archive
Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.
Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.
Scientists have long been worried about the possible harmful effects of regular cellular phone use, but so far no study has managed to produce clear results. Currently, cell phones are classified as carcinogenic category 2b - potentially carcinogenic to humans - by the International Agency for Research on Cancer (IARC).
A new study has shown aspirin cuts down the death rates from a range of cancers. The study reviewed data from eight previous trials involving more than 25,000 patients found that those who took just 75mg of aspirin a day (one-eighth of a normal dose) could reduce their death rates from cancer by 21% with benefits continuing long after patients stopped taking the pill.
Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course.
› Verified 2 days ago